Post-ischemic Treatment with Erythropoietin or Carbamylated Erythropoietin Reduces Infarction and Improves Neurological Outcome in a Rat Model of Focal Cerebral Ischemia.
From: Department of Neurology, Henry Ford Health Science Center, 2799 West Grand Boulevard, Detroit, MI 48202, USA.
British journal of pharmacology
- Publish Date: Aug 2007
- ISSN: 0007-1188
- Volume: 151
- Issue: 8
- Pages: 1377-84
- Medium: Print
- Language: English
- Citation (JAMA): Wang Y, Zhang Z G, Rhodes K, et al. Post-ischemic Treatment with Erythropoietin or Carbamylated Erythropoietin Reduces Infarction and Improves Neurological Outcome in a Rat Model of Focal Cerebral Ischemia.. Br. J. Pharmacol. Aug 2007;151:1377-84
Abstract
BACKGROUND AND PURPOSE: Recombinant human erythropoietin (rhEPO; Epoetin-alpha; PROCRITtrade mark) has been shown to exert neuroprotective and restorative effects in a variety of CNS injury models. However, limited information is available regarding the dose levels required for these beneficial effects or the neuronal responses that may underlie them. Here we have investigated the dose-response to rhEPO and compared the effects of rhEPO with those of carbamylated rhEPO (CEPO) in a model of cerebral stroke in rats. EXPERIMENTAL APPROACH: Rats subjected to embolic middle cerebral artery occlusion (MCAo) were treated with rhEPO or CEPO, starting at 6 h and repeated at 24 and 48 h, after MCAo. Cerebral infarct volumes were assessed at 28 days and neurological impairment at 7, 14, 21 and 28 days, post-MCAo. KEY RESULTS: rhEPO at dose levels of 500, 1150 or 5000 IU kg(-1) or CEPO at a dose level of 50 microg kg(-1) significantly reduced cortical infarct volume and reduced neurologic impairment. All doses of rhEPO, but not CEPO, produced a transient increase in haematocrit, while rhEPO and CEPO substantially reduced the number of apoptotic cells and activated microglia in the ischemic boundary region. CONCLUSIONS AND IMPLICATIONS: These data indicate that rhEPO and CEPO have anti-inflammatory and anti-apoptotic effects, even with administration at 6 h following embolic MCAo in rats. Taken together, these actions of rhEPO and CEPO are likely to contribute to their reduction of neurologic impairment following cerebral ischemia.
Mesh Headings (Keywords): Animals, Apoptosis, Blood-Brain Barrier, Brain Ischemia, Disease Models, Animal, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Epoetin Alfa, Erythropoietin, Hematinics, Hematocrit, Infarction, Middle Cerebral Artery, Male, Microglia, Neuroprotective Agents, Rats, Rats, Wistar, Stroke
Check for Full Text / PubMed Unique Identifier (PMID): 17603558
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.